This study investigates advanced pancreatic neuroendocrine tumors. It looks into combining two treatments to see how they work together.
The purpose of this study is to evaluate the safety and how well the combination treatment works. It checks the changes in tumor size and other responses.
- Who can participate: Adults aged 18 and older with a specific type of advanced pancreatic neuroendocrine tumor may participate. Eligibility requires adequate organ function and no prior similar treatments.
- Study details: Participants will receive investigational medication combined with Lu-DOTATATE.